---
figid: PMC9511812__cdr-5-3-762.fig.2
figtitle: An overview of resistance to chemotherapy in osteosarcoma and future perspectives
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC9511812
filename: cdr-5-3-762.fig.2.jpg
figlink: /pmc/articles/PMC9511812/figure/fig2/
number: F2
caption: 'Role of Family HER Pathway in osteosarcoma chemotherapy resistance. (A)
  Cisplatin resistance is associated with HER2 overexpression, PI3K/AKT activation
  and promotion p21 nuclear exclusion, favoring cell cycle arrest and proliferation.
  (B) Anti-EGFR therapy such as cetuximab and gefitinib sensitized osteosarcoma cells
  to DOX and MTX. (C) Afatinib a pan-HER Family inhibitor have an inhibition effect
  in osteosarcoma cell proliferation, migration an invasion. (D) Trastuzumab deruxtecan
  is an antibody-drug conjugated composed by anti-HER2 humanized monoclonal antibody
  and a topoisomerase I inhibitor as cytotoxic drug, that is now been tasted in clinical
  trials. AKT: Protein kinase B; DOX: doxorubicin; EGFR: epidermal growth factor receptor;
  ERK: extracellular signal-regulated kinase; HER: human epidermal growth factor;
  MTX: methotrexate; PI3K/AKT: phosphoinositide 3-kinase.'
papertitle: An overview of resistance to chemotherapy in osteosarcoma and future perspectives.
reftext: Dorian Yarih Garcia-Ortega, et al. Cancer Drug Resist. 2022;5(3):762-793.
year: '2022'
doi: 10.20517/cdr.2022.18
journal_title: Cancer Drug Resistance
journal_nlm_ta: Cancer Drug Resist
publisher_name: OAE Publishing Inc.
keywords: Osteosarcoma | therapy resistance | tyrosine kinase inhibitor | tumoral
  extracellular microenvironment | cell cycle
automl_pathway: 0.9700279
figid_alias: PMC9511812__F2
figtype: Figure
redirect_from: /figures/PMC9511812__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9511812__cdr-5-3-762.fig.2.html
  '@type': Dataset
  description: 'Role of Family HER Pathway in osteosarcoma chemotherapy resistance.
    (A) Cisplatin resistance is associated with HER2 overexpression, PI3K/AKT activation
    and promotion p21 nuclear exclusion, favoring cell cycle arrest and proliferation.
    (B) Anti-EGFR therapy such as cetuximab and gefitinib sensitized osteosarcoma
    cells to DOX and MTX. (C) Afatinib a pan-HER Family inhibitor have an inhibition
    effect in osteosarcoma cell proliferation, migration an invasion. (D) Trastuzumab
    deruxtecan is an antibody-drug conjugated composed by anti-HER2 humanized monoclonal
    antibody and a topoisomerase I inhibitor as cytotoxic drug, that is now been tasted
    in clinical trials. AKT: Protein kinase B; DOX: doxorubicin; EGFR: epidermal growth
    factor receptor; ERK: extracellular signal-regulated kinase; HER: human epidermal
    growth factor; MTX: methotrexate; PI3K/AKT: phosphoinositide 3-kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Rpn3
  - Dox-3
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - MKP-4
  - p38b
  - rl
  - Erk7
  - dap
  - EGFR
  - ERBB2
  - MTX1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - EPHB2
  - ERBB3
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
---
